Chohan Saima, Becker Michael A
Department of Medicine, University of Chicago Pritzker School of Medicine, Illinois, USA.
Curr Opin Rheumatol. 2009 Mar;21(2):143-9. doi: 10.1097/BOR.0b013e328325bd94.
To discuss currently available urate-lowering therapeutic options for gout in the United States and newer therapeutic initiatives in development.
Currently available urate-lowering drugs include allopurinol and probenecid. These drugs are effective but are often underdosed or underutilized, and caution must be taken in patients with multiple comorbidities. Newer therapeutic agents in development include febuxostat, a nonpurine analogue xanthine oxidase inhibitor, and pegloticase, a pegylated recombinant uricase.
There have been no new US Food and Drug Administration-approved urate-lowering drugs for gout in the past 40 years. Recent advances in therapeutics promise to provide the opportunity for much needed improvement in patient outcomes in this disorder.
讨论美国目前可用于痛风的降尿酸治疗方案以及正在研发的新治疗方案。
目前可用的降尿酸药物包括别嘌醇和丙磺舒。这些药物有效，但常常剂量不足或未得到充分利用，对于患有多种合并症的患者必须谨慎使用。正在研发的新治疗药物包括非嘌呤类似物黄嘌呤氧化酶抑制剂非布索坦和聚乙二醇化重组尿酸酶培戈洛酶。
在过去40年里，美国食品药品监督管理局没有批准用于痛风的新降尿酸药物。治疗方面的最新进展有望为改善这种疾病患者的预后提供急需的机会。
Zotero 插件